Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,410.64
(
0.13%
)
US TECH 100
28,420.40
(
0.46%
)
Dow Jones
49,530.10
(
-0.46%
)
Brent Oil
105.21
(
-0.52%
)
Bitcoin
79,609.61
(
-1.09%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

goodJohnhunting

Send PM Follow Ignore
Followers 35
Posts 1202
Boards Moderated 1
Alias Born 08/27/2000

goodJohnhunting

Member Level

Re: vinmantoo post# 305536

Wednesday, 07/26/2017 10:50:47 AM

Wednesday, July 26, 2017 10:50:47 AM

Post# of 347009
This is called, "endogenous protein cross reactivity".

In other words a lot of biologic competition for a clumsy therapeutic, IMO.

They could theoretically eliminate some competition by introducing specific statin combination that would reduce b2gp1 antigen presentation (from domain V2 epitope) to LDL receptor. Just saying..

Also, if ever a molecule needed exact PK data, this would be it.

All the best,
John

Disclaimer: Every post, and all my views are only speculative. Do not invest money or any other resources based on these post or opinions. Best of luck and do your own due diligence!

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote